Women who took estrogen-only menopausal hormone therapy had 39% lower odds of being diagnosed with dementia during their lifetime, according to a Stanford Medicine-led analysis of 21,462 women published August 12, 2026 in Neurology. At autopsy, the same group also showed 35% lower odds of the brain changes that define Alzheimer's disease.
The finding applies only to estrogen-only formulations taken orally, not to topical estrogen or to the combined estrogen-plus-progestin therapy that many women take for menopause symptoms today. The study is observational, meaning it can point to an association but cannot prove estrogen protects the brain.
The Stanford team pulled records from two national Alzheimer's research cohorts. Of the 21,462 women in the pooled dataset, 1,953 had used menopausal hormone therapy and 19,509 had not, ScienceDaily reported. The autopsy arm compared 258 brains from estrogen-only users with 2,701 brains from women who had reported no use of any form of the therapy.
What the autopsies actually showed
Researchers examined three markers pathologists use to diagnose Alzheimer's, namely amyloid plaques, tau-related neurofibrillary tangles and neuritic plaques. Among therapy users, 18% of the autopsied brains showed no Alzheimer's signs at all and 40% had all three markers. Among non-users, only 10% were free of signs and 51% carried all three.
Also read: Your sleep tracker may be making your sleep worse - and here is why
Women on estrogen-only therapy also performed better on memory tests and on measures of everyday functional independence, Time reported from the Stanford data.
A timing caveat that matters
The women in the databases began hormone therapy at an average age of about 70. That is later than the window most clinicians favor today, which the Stanford authors described as "during or soon after menopause." Earlier research has similarly suggested that starting hormone therapy early in menopause may shift its risk-benefit profile.
Senior author Hadi Hosseini, an associate professor of psychiatry and behavioral sciences at Stanford, told Science News that the study is the first to examine substantial numbers of postmortem Alzheimer's outcomes rather than relying on cognitive tests or clinical ratings alone.
The Women's Health Initiative shadow
For two decades, findings from the Women's Health Initiative left many clinicians wary of prescribing menopausal hormone therapy for brain health. Co-author Jennifer Bruno, an instructor in psychiatry and behavioral sciences at Stanford, said the long-standing recommendation had been "Don't use MHT for memory decline", a stance she said the new study "flies in the face of."
Also read: Every plant-based meat tested contained a fungal toxin - here's what the levels mean
Gayatri Devi of the Zucker School of Medicine, who was not involved in the study, told Science News that the work "adds an important piece to the evolving evidence on menopausal hormone therapy (MHT) and brain health."
The Stanford team could not draw conclusions about estrogen-plus-progestin combinations because too few women in the datasets used them. Women weighing hormone therapy for menopause symptoms should discuss the specific formulation, timing and their personal risk factors with their doctor before starting or changing treatment.
Also read: Intermittent fasting vs. calorie restriction: which actually works better?
This article is made and published by Jesper Bengtson, who may have used AI in the preparation.